Myelin repair and functional recovery mediated by neural cell transplantation in a mouse model of multiple sclerosis

Neuroscience Bulletin

Volumn 29, Issue 2, 2013, Pages 239-250

  Bai, Lianhua ^a,b   Hecker, Jordan ^a   Kerstetter, Amber ^a   Miller, Robert H ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

experimental autoimmune encephalomyelitis; multiple sclerosis; myelin; NG2 glycoprotein; oligodendrocytes; remyelination

Indexed keywords

GLYCOPROTEIN; GLYCOPROTEIN NG2; UNCLASSIFIED DRUG;

ADULT ANIMAL; ALLERGIC ENCEPHALOMYELITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CD3+ T LYMPHOCYTE; CELL POPULATION; CELL TRANSPLANTATION; CONTROLLED STUDY; FEMALE; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; MOUSE; MULTIPLE SCLEROSIS; NERVE CELL; NONHUMAN; PROTEIN EXPRESSION; REMYELINIZATION; SPINAL CORD; TISSUE REPAIR;

ANIMALS; ANIMALS, NEWBORN; ANTIGENS; ANTIGENS, CD3; BROMODEOXYURIDINE; CELL TRANSPLANTATION; CELLS, CULTURED; CULTURE MEDIA, CONDITIONED; DISEASE MODELS, ANIMAL; FEMALE; GLIAL FIBRILLARY ACIDIC PROTEIN; GREEN FLUORESCENT PROTEINS; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MULTIPLE SCLEROSIS; MYELIN PROTEOLIPID PROTEIN; MYELIN-OLIGODENDROCYTE GLYCOPROTEIN; NEURONS; OLIGODENDROGLIA; ORGAN CULTURE TECHNIQUES; PEPTIDE FRAGMENTS; PROTEOGLYCANS; PROTO-ONCOGENE PROTEINS C-SIS; RECOVERY OF FUNCTION; SPINAL CORD; TIME FACTORS;

EID: 84877874311     PISSN: 16737067     EISSN: 19958218     Source Type: Journal    
DOI: 10.1007/s12264-013-1312-4     Document Type: Article

References (60)

1. Miller RH. The promise of stem cells for neural repair. Brain Res 2006, 1091: 258-264.
2. Miller RH, Bai L, Lennon DP, Caplan AI. The potential of mesenchymal stem cells for neural repair. Discov Med 2010, 9: 236-242.
3. Bai L, Lennon DP, Eaton V, Maier K, Caplan AI, Miller SD, et al. Human bone marrow-derived mesenchymal stem cells induce Th2-polarized immune response and promote endogenous repair in animal models of multiple sclerosis. Glia 2009, 57: 1192-1203.
4. Sharp J, Keirstead HS. Stem cell-based cell replacement strategies for the central nervous system. Neurosci Lett 2009, 456: 107-111.
5. Auletta JJ, Bartholomew AM, Maziarz RT, Deans RJ, Miller RH, Lazarus HM, et al. The potential of mesenchymal stromal cells as a novel cellular therapy for multiple sclerosis. Immunotherapy 2012, 4: 529-547.
6. Bai L, Lennon DP, Caplan AI, DeChant A, Hecker J, Kranso J, et al. Hepatocyte growth factor mediates mesenchymal stem cell-induced recovery in multiple sclerosis models. Nat Neurosci 2012, 15: 862-870.
7. Ben-Hur T. Cell therapy for multiple sclerosis. Neurotherapeutics 2011, 8: 625-642.
8. Pluchino S, Quattrini A, Brambilla E, Gritti A, Salani G, Dina G, et al. Injection of adult neurospheres induces recovery in a chronic model of multiple sclerosis. Nature 2003, 422: 688-694.
9. Bassi G, Pacelli L, Carusone R, Zanoncello J, Krampera M. Adipose-derived stromal cells (ASCs). Transfus Apher Sci 2012, 47: 193-198.
10. Fouraschen SM, Pan Q, de Ruiter PE, Farid WR, Kazemier G, Kwekkeboom J, et al. Secreted factors of human liver-derived mesenchymal stem cells promote liver regeneration early after partial hepatectomy. Stem Cells Dev 2012, 21: 2410-2419.
11. Hoffman AM, Paxson JA, Mazan MR, Davis AM, Tyagi S, Murthy S, et al. Lung-derived mesenchymal stromal cell post-transplantation survival, persistence, paracrine expression, and repair of elastase-injured lung. Stem Cells Dev 2011, 20: 1779-1792.
12. Huang Y, Chen P, Zhang CB, Ko GJ, Ruiz M, Fiorina P, et al. Kidney-derived mesenchymal stromal cells modulate dendritic cell function to suppress alloimmune responses and delay allograft rejection. Transplantation 2010, 90: 1307-1311.
13. Caplan AI. All MSCs are pericytes? Cell Stem Cell 2008, 3: 229-230.
14. Vaculik C, Schuster C, Bauer W, Iram N, Pfisterer K, Kramer G, et al. Human dermis harbors distinct mesenchymal stromal cell subsets. J Invest Dermatol 2012, 132: 563-574.
15. Caplan AI. New era of cell-based orthopedic therapies. Tissue Eng Part B Rev 2009, 15: 195-200.
16. Caplan AI, Correa D. PDGF in bone formation and regeneration: new insights into a novel mechanism involving MSCs. J Orthop Res 2011, 29: 1795-1803.
17. Dore-Duffy P, Mehedi A, Wang X, Bradley M, Trotter R, Gow A. Immortalized CNS pericytes are quiescent smooth muscle actin-negative and pluripotent. Microvasc Res 2011, 82: 18-27.
18. Canfield AE, Sutton AB, Hoyland JA, Schor AM. Association of thrombospondin-1 with osteogenic differentiation of retinal pericytes in vitro. J Cell Sci 1996, 109(Pt 2): 343-353.
19. Doherty MJ, Ashton BA, Walsh S, Beresford JN, Grant ME, Canfield AE. Vascular pericytes express osteogenic potential in vitro and in vivo. J Bone Miner Res 1998, 13: 828-838.
20. Dore-Duffy P. Pericytes: pluripotent cells of the blood brain barrier. Curr Pharm Des 2008, 14: 1581-1593.
21. Hirschi KK, D'Amore PA. Pericytes in the microvasculature. Cardiovasc Res 1996, 32: 687-698.
22. Lundberg C, Martinez-Serrano A, Cattaneo E, McKay RD, Bjorklund A. Survival, integration, and differentiation of neural stem cell lines after transplantation to the adult rat striatum. Exp Neurol 1997, 145: 342-360.
23. Ozerdem U, Stallcup WB. Pathological angiogenesis is reduced by targeting pericytes via the NG2 proteoglycan. Angiogenesis 2004, 7: 269-276.
24. Stallcup WB. The NG2 proteoglycan: past insights and future prospects. J Neurocytol 2002, 31: 423-435.
25. Nishiyama A. Polydendrocytes: NG2 cells with many roles in development and repair of the CNS. Neuroscientist 2007, 13: 62-76.
26. Stallcup WB. The NG2 antigen, a putative lineage marker: immunofluorescent localization in primary cultures of rat brain. Dev Biol 1981, 83: 154-165.
27. Zhu X, Hill RA, Nishiyama A. NG2 cells generate oligodendrocytes and gray matter astrocytes in the spinal cord. Neuron Glia Biol 2008, 4: 19-26.
28. Nishiyama A, Komitova M, Suzuki R, Zhu X. Polydendrocytes (NG2 cells): multifunctional cells with lineage plasticity. Nat Rev Neurosci 2009, 10: 9-22.
29. Karadottir R, Hamilton NB, Bakiri Y, Attwell D. Spiking and nonspiking classes of oligodendrocyte precursor glia in CNS white matter. Nat Neurosci 2008, 11: 450-456.
30. MacFadyen J, Savage K, Wienke D, Isacke CM. Endosialin is expressed on stromal fibroblasts and CNS pericytes in mouse embryos and is downregulated during development. Gene Expr Patterns 2007, 7: 363-369.
31. Shepro D, Morel NM. Pericyte physiology. FASEB J 1993, 7: 1031-1038.
32. Edelman DA, Jiang Y, Tyburski J, Wilson RF, Steffes C. Pericytes and their role in microvasculature homeostasis. J Surg Res 2006, 135: 305-311.
33. von Tell D, Armulik A, Betsholtz C. Pericytes and vascular stability. Exp Cell Res 2006, 312: 623-629.
34. Balabanov R, Dore-Duffy P. Role of the CNS microvascular pericyte in the blood-brain barrier. J Neurosci Res 1998, 53: 637-644.
35. Ballabh P, Braun A, Nedergaard M. The blood-brain barrier: an overview: structure, regulation, and clinical implications. Neurobiol Dis 2004, 16: 1-13.
36. Dore-Duffy P, Katychev A, Wang X, Van Buren E. CNS microvascular pericytes exhibit multipotential stem cell activity. J Cereb Blood Flow Metab 2006, 26: 613-624.
37. Wight PA, Duchala CS, Shick HE, Gudz TI, Macklin WB. Expression of a myelin proteolipid protein (Plp)-lacZ transgene is reduced in both the CNS and PNS of Plp(jp) mice. Neurochem Res 2007, 32: 343-351.
38. Garbelli R, Zucca I, Milesi G, Mastropietro A, D'Incerti L, Tassi L, et al. Combined 7-T MRI and histopathologic study of normal and dysplastic samples from patients with TLE. Neurology 2011, 76: 1177-1185.
39. Sun HS, French RJ, Feng ZP. A method for identifying viable and damaged neurons in adult mouse brain slices. Acta Histochem 2009, 111: 531-537.
40. Jariyapongskul A, Nakano A, Yamaguchi S, Nageswari K, Niimi H. Maturity of pericytes in cerebral neocapillaries induced by growth factors: fluorescence immuno-histochemical analysis using confocal laser microscopy. Clin Hemorheol Microcirc 2003, 29: 417-421.
41. Sims DE. The pericyte - a review. Tissue Cell 1986, 18: 153-174.
42. Orlidge A, D'Amore PA. Cell specific effects of glycosaminoglycans on the attachment and proliferation of vascular wall components. Microvasc Res 1986, 31: 41-53.
43. Yang Z, Watanabe M, Nishiyama A. Optimization of oligodendrocyte progenitor cell culture method for enhanced survival. J Neurosci Methods 2005, 149: 50-56.
44. Kucharova K, Chang Y, Boor A, Yong VW, Stallcup WB. Reduced inflammation accompanies diminished myelin damage and repair in the NG2 null mouse spinal cord. J Neuroinflammation 2011, 8: 158.
45. Tripathi RB, Rivers LE, Young KM, Jamen F, Richardson WD. NG2 glia generate new oligodendrocytes but few astrocytes in a murine experimental autoimmune encephalomyelitis model of demyelinating disease. J Neurosci 2010, 30: 16383-16390.
46. Pringle N, Collarini EJ, Mosley MJ, Heldin CH, Westermark B, Richardson WD. PDGF A chain homodimers drive proliferation of bipotential (O-2A) glial progenitor cells in the developing rat optic nerve. EMBO J 1989, 8: 1049-1056.
47. Tsai HH, Macklin WB, Miller RH. Distinct modes of migration position oligodendrocyte precursors for localized cell division in the developing spinal cord. J Neurosci Res 2009, 87: 3320-3330.
48. Kaplan JM, Youd ME, Lodie TA. Immunomodulatory activity of mesenchymal stem cells. Curr Stem Cell Res Ther 2011, 6: 297-316.
49. Payne NL, Sun G, Herszfeld D, Tat-Goh PA, Verma PJ, Parkington HC, et al. Comparative study on the therapeutic potential of neurally differentiated stem cells in a mouse model of multiple sclerosis. PLoS One 2012, 7: e35093.
50. Miller RH, Bai L. Translating stem cell therapies to the clinic. Neurosci Lett 2012, 519: 87-92.
51. Busch SA, Horn KP, Cuascut FX, Hawthorne AL, Bai L, Miller RH, et al. Adult NG2+ cells are permissive to neurite outgrowth and stabilize sensory axons during macrophageinduced axonal dieback after spinal cord injury. J Neurosci 2010, 30: 255-265.
52. Whitman LM, Blanc CA, Schaumburg CS, Rowitch DH, Lane TE. Olig1 function is required for remyelination potential of transplanted neural progenitor cells in a model of viral-induced demyelination. Exp Neurol 2012, 235: 380-387.
53. Kondo T, Raff M. Oligodendrocyte precursor cells reprogrammed to become multipotential CNS stem cells. Science 2000, 289: 1754-1757.
54. Nishiyama A, Yang Z, Butt A. Astrocytes and NG2-glia: what's in a name? J Anat 2005, 207: 687-693.
55. Dincman TA, Beare JE, Ohri SS, Whittemore SR. Isolation of cortical mouse oligodendrocyte precursor cells. J Neurosci Methods 2012, 209: 219-226.
56. Staugaitis SM, Trapp BD. NG2-positive glia in the human central nervous system. Neuron Glia Biol 2009, 5: 35-44.
57. Carlesi C, Pasquali L, Piazza S, Lo Gerfo A, Caldarazzo Ienco E, Alessi R, et al. Strategies for clinical approach to neurodegeneration in Amyotrophic lateral sclerosis. Arch Ital Biol 2011, 149: 151-167.
58. Naganska E, Matyja E. Amyotrophic lateral sclerosis - looking for pathogenesis and effective therapy. Folia Neuropathol 2011, 49: 1-13.
59. Lepore AC, Dejea C, Carmen J, Rauck B, Kerr DA, Sofroniew MV, et al. Selective ablation of proliferating astrocytes does not affect disease outcome in either acute or chronic models of motor neuron degeneration. Exp Neurol 2008, 211: 423-432.
60. Kang SH, Fukaya M, Yang JK, Rothstein JD, Bergles DE. NG2+ CNS glial progenitors remain committed to the oligodendrocyte lineage in postnatal life and following neurodegeneration. Neuron 2010, 68: 668-681.